Tumor-infiltrating B cells and plasma cells (TIL-Bs), as part of TIICs, from cancer patients also express antibodies targeting p53 [64–69], and TIL-Bs are associated with better survival in most cancers [64]. This evidence concerns the gene TP53 and cancer.